About puma biotechnology inc - PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
PBYI At a Glance
Puma Biotechnology, Inc.
10880 Wilshire Boulevard
Los Angeles, California 90024-4101
| Phone | 1-424-248-6500 | Revenue | 228.37M | |
| Industry | Pharmaceuticals: Major | Net Income | 31.11M | |
| Sector | Health Technology | Employees | 179 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PBYI Valuation
| P/E Current | 16.108 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 9.687 |
| Price to Sales Ratio | 1.32 |
| Price to Book Ratio | 2.301 |
| Price to Cash Flow Ratio | 7.21 |
| Enterprise Value to EBITDA | 4.775 |
| Enterprise Value to Sales | 1.009 |
| Total Debt to Enterprise Value | 0.124 |
PBYI Efficiency
| Revenue/Employee | 1,275,815.642 |
| Income Per Employee | 173,804.469 |
| Receivables Turnover | 4.256 |
| Total Asset Turnover | 1.056 |
PBYI Liquidity
| Current Ratio | 2.002 |
| Quick Ratio | 1.934 |
| Cash Ratio | 1.226 |
PBYI Profitability
| Gross Margin | 74.534 |
| Operating Margin | 16.333 |
| Pretax Margin | 15.668 |
| Net Margin | 13.623 |
| Return on Assets | 14.389 |
| Return on Equity | 27.969 |
| Return on Total Capital | 19.581 |
| Return on Invested Capital | 24.85 |
PBYI Capital Structure
| Total Debt to Total Equity | 21.901 |
| Total Debt to Total Capital | 17.966 |
| Total Debt to Total Assets | 13.115 |
| Long-Term Debt to Equity | 3.613 |
| Long-Term Debt to Total Capital | 2.964 |